For every patient still waiting

At Attovia, we understand the daily impact that chronic inflammatory and immunologic diseases have on patients, caregivers, and families. Conditions like atopic dermatitis, IBD, and chronic pruritus take a profound toll-physically, emotionally, and socially. And for too many, today’s treatments still fall short. That’s why we’re developing a new generation of multispecific medicines designed to break through the efficacy ceiling, work faster, and last longer.

We’re driven by one goal: to change what patients can expect from their treatments—and from their futures.

For every patient still waiting

At Attovia, we understand the daily impact that chronic inflammatory and immunologic diseases have on patients, caregivers, and families. Conditions like atopic dermatitis, IBD, and chronic pruritus take a profound toll-physically, emotionally, and socially. And for too many, today’s treatments still fall short. That’s why we’re developing a new generation of multispecific medicines designed to break through the efficacy ceiling, work faster, and last longer.

We’re driven by one goal: to change what patients can expect from their treatments—and from their futures.

Learn more about our clinical programs:

Phase 1 trial of ATTO-1310 (anti-IL31)

This study will first evaluate the safety and tolerability of ATTO-1310 in healthy adults after receiving single and multiple doses. The study will then evaluate the effect of a single dose of ATTO-1310 in adult patients with severe itching and either atopic dermatitis or chronic pruritus. All participants will be followed in the study for approximately 16 weeks after the last dose.

Phase 1 trial of ATTO-3712 (anti-IL31 x IL13)

This study will first evaluate the safety and tolerability of ATTO-3712 in healthy adults after receiving single and multiple doses. The study will then evaluate the effect of two doses of ATTO-3712 in adult patients with moderate to severe atopic dermatitis. All participants will be followed in the study for approximately 16 weeks after the last dose.